Finch Therapeutics Group Inc (FNCH)
0.9670
0.00 (0.00%)
USD |
OTCM |
May 31, 16:00
Finch Therapeutics Group Enterprise Value: -19.21M for May 31, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 31, 2024 | -19.21M |
| May 30, 2024 | -19.20M |
| May 29, 2024 | -19.35M |
| May 28, 2024 | -18.82M |
| May 24, 2024 | -17.87M |
| May 23, 2024 | -17.58M |
| May 22, 2024 | -17.34M |
| May 21, 2024 | -17.04M |
| May 20, 2024 | -17.16M |
| May 17, 2024 | -17.65M |
| May 16, 2024 | -17.68M |
| May 15, 2024 | -17.39M |
| May 14, 2024 | -17.65M |
| May 13, 2024 | -17.74M |
| May 10, 2024 | -17.53M |
| May 09, 2024 | -17.50M |
| May 08, 2024 | -17.36M |
| May 07, 2024 | -17.26M |
| May 06, 2024 | -17.18M |
| May 03, 2024 | -17.07M |
| May 02, 2024 | -16.76M |
| May 01, 2024 | -17.05M |
| April 30, 2024 | -17.16M |
| April 29, 2024 | -17.07M |
| April 26, 2024 | -17.04M |
| Date | Value |
|---|---|
| April 25, 2024 | -17.16M |
| April 24, 2024 | -17.07M |
| April 23, 2024 | -16.28M |
| April 22, 2024 | -17.05M |
| April 19, 2024 | -17.16M |
| April 18, 2024 | -16.97M |
| April 17, 2024 | -16.72M |
| April 16, 2024 | -15.78M |
| April 15, 2024 | -17.16M |
| April 12, 2024 | -17.50M |
| April 11, 2024 | -16.99M |
| April 10, 2024 | -16.83M |
| April 09, 2024 | -16.82M |
| April 08, 2024 | -17.23M |
| April 05, 2024 | -17.23M |
| April 04, 2024 | -17.08M |
| April 03, 2024 | -16.91M |
| April 02, 2024 | -16.81M |
| April 01, 2024 | -16.67M |
| March 28, 2024 | -20.95M |
| March 27, 2024 | -20.48M |
| March 26, 2024 | -20.88M |
| March 25, 2024 | -20.79M |
| March 22, 2024 | -21.00M |
| March 21, 2024 | -20.93M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-53.41M
Minimum
Dec 23 2022
907.23M
Maximum
Mar 19 2021
132.31M
Average
-9.460M
Median
Sep 27 2022
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals Inc | 2.021B |
| Vanda Pharmaceuticals Inc | -95.58M |
| Sage Therapeutics Inc | -48.99M |
| BioSig Technologies Inc | 25.19M |
| Palisade Bio Inc | -6.817M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.876M |
| Total Expenses (Quarterly) | 5.164M |
| EPS Diluted (Quarterly) | -2.41 |
| Earnings Yield | -1.05K% |
| Normalized Earnings Yield | -5010.66 |